Ratings Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-02 EST			5-day change	1st Jan Change
44.26 ^USD	+2.79%		+1.37%	-55.50%

11-26	Triple trouble
11-26	JPMorgan Adjusts Price Target on Moderna to $45 From $59, Maintains Underweight Rating	MT

Summary: Moderna, Inc.

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Highlights: Moderna, Inc.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Moderna, Inc.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 2.56 times its current sales, is high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: Moderna, Inc.

Source: Surperformance

ESG chart: Moderna, Inc.

Source: Refinitiv

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
MODERNA, INC.	-	16.57B
LONZA GROUP AG		43.12B
IQVIA HOLDINGS INC.		36.45B
CELLTRION, INC.		27.58B
ICON PUBLIC LIMITED COMPANY		17.36B
UNITED THERAPEUTICS CORPORATION		16.54B
BIO-TECHNE CORPORATION		11.97B
MEDPACE HOLDINGS, INC.		10.56B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		10.18B
Average		21.15B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

B-

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes